-
公开(公告)号：US08425935B2
公开(公告)日：2013-04-23
申请号：US12158236
申请日：2006-12-11
CPC分类号： A61K9/0056 , A61K9/2018
摘要： A pharmaceutical formulation in the form of agglomerates comprising a) 60-97% by weight of sugar or sugar alcohols, b) 1-25% by weight of crosslinked polyvinylpyrrolidone, c) 1-15% by weight of water-insoluble, film-forming polymers, d) 0-15% by weight of water-soluble polymers and e) 0-15% by weight of further pharmaceutically customary excipients, the sum of the components a) to e) being 100% by weight.
摘要翻译： 附聚物形式的药物制剂，其包含a）60-97重量％的糖或糖醇，b）1-25重量％的交联聚乙烯吡咯烷酮，c）1-15重量％的不溶于水的， 形成聚合物，d）0-15重量％的水溶性聚合物和e）0-15重量％的其它药学上常规的赋形剂，组分a）至e）的总和为100重量％。
-
公开(公告)号：US20080299194A1
公开(公告)日：2008-12-04
申请号：US12158236
申请日：2006-12-11
CPC分类号： A61K9/0056 , A61K9/2018
摘要： A pharmaceutical formulation in the form of agglomerates comprising a) 60-97% by weight of sugar or sugar alcohols, b) 1-25% by weight of crosslinked polyvinylpyrrolidone, c) 1-15% by weight of water-insoluble, film-forming polymers, d) 0-15% by weight of water-soluble polymers and e) 0-15% by weight of further pharmaceutically customary excipients, the sum of the components a) to e) being 100% by weight.
摘要翻译： 附聚物形式的药物制剂，其包含a）60-97重量％的糖或糖醇，b）1-25重量％的交联聚乙烯吡咯烷酮，c）1-15重量％的不溶于水的， 形成聚合物，d）0-15重量％的水溶性聚合物和e）0-15重量％的其它药学上常规的赋形剂，组分a）至e）的总和为100重量％。
-
3.发明申请Pharmaceutical dosage forms with impeded extractability of a sympathomimetic 审中-公开具有阻碍的交感神经的可提取性的药物剂型公开(公告)号：US20060062847A1
公开(公告)日：2006-03-23
申请号：US11225176
申请日：2005-09-14
申请人： Karl Kolter , Marcus Wichtner , Kathrin Meyer , Heinz Einig
发明人： Karl Kolter , Marcus Wichtner , Kathrin Meyer , Heinz Einig
CPC分类号： A61K31/185 , A61K9/2009 , A61K9/205 , A61K9/2054
摘要： A solid oral pharmaceutical dosage form of a sympathomimetic with impeded extractability of the sympathomimetic, comprising I) a sympathomimetic (component I) II) an excipient mixture (component II) composed of a) 5 to 50% by weight of hydroxyalkylcelluloses or alkylcelluloses or mixtures thereof b) 5 to 70% by weight of xanthan c) 5 to 50% by weight of an alkaline earth metal salt of a C10-C30 fatty acid d) 10 to 70% by weight of an alkali metal or alkaline earth metal salt of a mineral acid, of a sulfonic acid or of a C2-C6 carboxylic acid or mixtures thereof, where the total of components a) to d) is 100% by weight, where the ratio of active ingredient to excipient mixture II) is from 1:2 to 3:1 by weight.
摘要翻译： 包含I）拟交感神经元（组分I）II）赋形剂混合物（组分II）的固体口服药物剂型，其具有妨碍所述交感神经活性的可提取性，其包含a）5至50重量％的羟烷基纤维素或烷基纤维素或混合物 b）5〜70重量％的呫吨
-
-
搜索结果
3 条记录 (耗时 0.021 秒)
